Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082280 | 0.91 | PDK2 (0.33) | PDK2 | |
| SCHEMBL5082359 | 0.89 | SMN1; SMN2 (0.34) | CYP2C19APEX1KMT2ASMN1; SMN2 | |
| SCHEMBL5078718 | 0.89 | APEX1 (0.39) | CYP2C9CYP2C19NPSR1APEX1KMT2A | |
| SCHEMBL5085242 | 0.88 | PDK2 (0.33) | CYP2C9CYP2C19NPSR1PDK2APEX1 | |
| SCHEMBL5084607 | 0.86 | PDK2 (0.35) | CYP2C9CYP2C19NPSR1PDK2APEX1 | |
| SCHEMBL30322467 | 0.84 | PDK2 (0.40) | CYP2C9CYP2C19NPSR1PDK2APEX1 | |
| SCHEMBL20995933 | 0.84 | PDK2 (0.40) | CYP2C9CYP2C19NPSR1PDK2APEX1 | |
| SCHEMBL5081777 | 0.83 | PDK2 (0.33) | CYP2C9CYP2C19NPSR1PDK2APEX1 | |
| SCHEMBL5082283 | 0.83 | PDK2 (0.30) | PDK2 | |
| SCHEMBL5080869 | 0.83 | APEX1 (0.35) | PDK2APEX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142146-A1 | Catalyst for olefin polymerization and use of the same | CHINA PETROLEUM & CHEMICAL CORPORATION | 2006-06-29 | — | — | US | claimed |
| US-6822109-B2 | TRIHYDROCARBYLSILYLATION; ADDITION POLYMERIZATION OF OLEFINS | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2004-11-23 | — | — | US | claimed |
| US-20040106814-A1 | Silicon ether compound, a method for the preparation thereof and use thereof | BEIJING RESEARCH INSTITUTE OF CHEMICAL INDUSTRY, CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2004-06-03 | — | — | US | claimed |
| US-7323431-B2 | Catalyst for olefin polymerization and use of the same | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-01-29 | — | — | US | disclosed |
| US-20060142146-A1 | Catalyst for olefin polymerization and use of the same | CHINA PETROLEUM & CHEMICAL CORPORATION | 2006-06-29 | — | — | US | disclosed |
| US-6822109-B2 | TRIHYDROCARBYLSILYLATION; ADDITION POLYMERIZATION OF OLEFINS | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2004-11-23 | — | — | US | disclosed |
| US-20040106814-A1 | Silicon ether compound, a method for the preparation thereof and use thereof | BEIJING RESEARCH INSTITUTE OF CHEMICAL INDUSTRY, CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106814-A1 | Silicon ether compound, a method for the preparation thereof and use thereof | SIK1, CDK20, SGMS1 | CYP2C9 920/4885CYP2C19 588/4885NPSR1 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.